BACKGROUND: The role of smoking as a risk factor for adverse renal outcomes after kidney transplant has not been well studied. We therefore undertook this investigation to assess the association of smoking with transplant outcomes. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: 997 consecutive laparoscopic live donor kidney transplant recipients at a tertiary-care transplant center. PREDICTOR: Smoking at the time of the transplant evaluation. OUTCOMES & MEASUREMENTS: Primary outcome is transplant survival. RESULTS: At the time of pretransplant evaluation, 329 participants had ever smoked and 668 participants had never smoked. Transplant survival was worse in ever smokers compared with never smokers (adjusted HR, 1.47; 95% CI, 1.08-1.99; P = 0.01), as was patient survival (adjusted HR, 1.60; 95% CI, 1.06-2.41; P = 0.02). First-year rejection-free survival was substantially worse (adjusted HR, 1.46; 95% CI, 1.05-2.03; P = 0.03) and risk of rejection on or before posttransplant day 10 was much higher (adjusted HR, 1.8; 95% CI, 1.10-2.94; P = 0.02) in ever smokers compared with never smokers. Glomerular filtration rate (estimated using the Modification of Diet in Renal Disease Study equation) at 1 year posttransplant was lower and poor early transplant function was more common in ever smokers on univariate, but not multivariate, analysis. LIMITATIONS: Lack of quantitation of smoking exposure and uncertainty about whether patients were still smoking at the time of transplant. CONCLUSIONS: Our results suggest that any history of smoking before transplant is associated with impaired transplant and patient survival and increases the risk of early rejection after live donor kidney transplant. Further study is needed to determine whether smoking may impart immunomodulatory and perhaps nephrotoxic effects. Copyright 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
BACKGROUND: The role of smoking as a risk factor for adverse renal outcomes after kidney transplant has not been well studied. We therefore undertook this investigation to assess the association of smoking with transplant outcomes. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: 997 consecutive laparoscopic live donor kidney transplant recipients at a tertiary-care transplant center. PREDICTOR: Smoking at the time of the transplant evaluation. OUTCOMES & MEASUREMENTS: Primary outcome is transplant survival. RESULTS: At the time of pretransplant evaluation, 329 participants had ever smoked and 668 participants had never smoked. Transplant survival was worse in ever smokers compared with never smokers (adjusted HR, 1.47; 95% CI, 1.08-1.99; P = 0.01), as was patient survival (adjusted HR, 1.60; 95% CI, 1.06-2.41; P = 0.02). First-year rejection-free survival was substantially worse (adjusted HR, 1.46; 95% CI, 1.05-2.03; P = 0.03) and risk of rejection on or before posttransplant day 10 was much higher (adjusted HR, 1.8; 95% CI, 1.10-2.94; P = 0.02) in ever smokers compared with never smokers. Glomerular filtration rate (estimated using the Modification of Diet in Renal Disease Study equation) at 1 year posttransplant was lower and poor early transplant function was more common in ever smokers on univariate, but not multivariate, analysis. LIMITATIONS: Lack of quantitation of smoking exposure and uncertainty about whether patients were still smoking at the time of transplant. CONCLUSIONS: Our results suggest that any history of smoking before transplant is associated with impaired transplant and patient survival and increases the risk of early rejection after live donor kidney transplant. Further study is needed to determine whether smoking may impart immunomodulatory and perhaps nephrotoxic effects. Copyright 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Authors: Muhammad Abdul Mabood Khalil; Jackson Tan; Said Khamis; Muhammad AshhadUllah Khalil; Rabeea Azmat; Arslan Rahat Ullah Journal: Adv Med Date: 2017-07-27
Authors: S Inés Lozano-Ramos; Ioana Bancu; Laura Carreras-Planella; Marta Monguió-Tortajada; Laura Cañas; Javier Juega; Josep Bonet; M Pilar Armengol; Ricardo Lauzurica; Francesc E Borràs Journal: BMC Nephrol Date: 2018-07-31 Impact factor: 2.388
Authors: Marina de Cos Gomez; Adalberto Benito Hernandez; Maria Teresa Garcia Unzueta; Jaime Mazon Ruiz; Covadonga Lopez Del Moral Cuesta; Jose Luis Perez Canga; David San Segundo Arribas; Rosalia Valero San Cecilio; Juan Carlos Ruiz San Millan; Emilio Rodrigo Calabia Journal: J Clin Med Date: 2020-12-20 Impact factor: 4.241
Authors: Ilias Zompolas; Robert Peters; Lutz Liefeldt; Lukas J Lehner; Klemens Budde; Bernhard Ralla; Irena Goranova; Andreas Maxeiner; Markus H Lerchbaumer; Stephan R Marticorena Garcia; Martin Kanne; Thorsten Schlomm; Matthias R G Schulz; Frank Friedersdorff Journal: J Clin Med Date: 2021-11-29 Impact factor: 4.241
Authors: Austin G Stack; Darya Yermak; David G Roche; John P Ferguson; Mohamed Elsayed; Waleed Mohammed; Liam F Casserly; Stewart R Walsh; Cornelius J Cronin Journal: BMC Nephrol Date: 2016-07-26 Impact factor: 2.388
Authors: Larry A Weinrauch; Brian Claggett; Jiankang Liu; Peter V Finn; Matthew R Weir; Daniel E Weiner; John A D'Elia Journal: Int J Nephrol Renovasc Dis Date: 2018-04-27